

Regimen Reference Order – BRST – PACLitaxel Metastatic every 21 days

ARIA: BRST – [PACLitaxel (MET) q21d]

Planned Course: Every 21 days until disease progression or unacceptable toxicity

Indication for Use: Breast Cancer Metastatic

CVAD: At Provider's Discretion

Proceed with treatment if:

ANC equal to or greater than $1.5 \times 10^9/L$ AND Platelets equal to or greater than $100 \times 10^9/L$

❖ Contact Physician if parameters not met

SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements

Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – BRST – PACLitaxel Metastatic every 21 days

Establish primary solution 500 mL of: normal saline

Drug	Dose	CCMB Administration Guideline
dexamethasone	20 mg	IV in normal saline 50 mL over 15 minutes
diphenhydrAMINE	50 mg	IV in normal saline 50 mL over 15 minutes
raNITidine	50 mg	IV in normal saline 50 mL over 15 minutes
metoclopramide	20 mg	Orally 30 minutes pre-chemotherapy
PACLitaxel	175 mg/m^2	IV in normal saline 500 mL over 3 hours <i>Use non-DEHP bags and non-DEHP administration sets with 0.22 micron in-line filter</i> <i>Concentration dependent drug: Pharmacy will adjust diluent volume to ensure drug stability</i>

Flush after each medication:

- 50 mL over 6 minutes (500 mL/hr)

In the event of an infusion-related hypersensitivity reaction, refer to the 'Hypersensitivity Reaction Standing Order'

REQUIRED MONITORING

All Cycles

- CBC, biochemistry as per physician order
- Full vital signs (temperature, heart rate, respiration, blood pressure and O₂ saturation) at baseline and as clinically indicated
- Monitor heart rate and blood pressure every 15 minutes for 1 hour, then hourly

Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 - 20 mg	Orally every 4 – 6 hours as needed for nausea and vomiting

DISCHARGE INSTRUCTIONS

- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

ADDITIONAL INFORMATION

- N/A